It is an Exciting Time for Patients

Last quarter,the FDA approved several exciting new therapies to improve patient’s lives.  Amgen’s Blincyto is a newly approved drug for patients with a form of acute lymphoblastic leukemia.  Blincyto will help save lives!  Abbvie recently reached approval for a Hepititas C therapy.  Abbvie reached 97 percent cure rate in a clinical trial.  BMS continues its success with Biologics with an approval for advanced melanoma with a therapy Opdivo.